Doximity, Inc.
NYSE:DOCSMedical - Healthcare Information Services
-$0.09 today
- Market cap
- $5.47B
- Beta
- 1.29
- P/E (TTM)
- 19.2
- EPS (TTM)
- $1.06
Volume 2.27M
Average 3.89M
DOCS Cash & Equivalents
Cash on hand and highly liquid investments that can be converted to cash almost immediately.
Doximity, Inc.NYSE: DOCS
Cash & Equivalents · Q2 FY2027 · quarter ended Sep 2026
Cash & equivalents rises 29.2% from a year ago
Cash & equivalents stood at $218.61M at the end of Q2 FY2027, up 29.2% from a year earlier and down 20.1% from the prior quarter. Over 3 fiscal years it compounded at +11.5% a year.
Context
- Cash & equivalents amounted to 20.0% of total assets at the end of Q2 FY2027, up 6.6 pp from a year earlier.
- Cash & equivalents increased in 2 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether cash & equivalents keeps rising in the next quarterly balance sheet after a +29.2% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Cash & Equivalents history
USD · from the balance sheet
- Latest · FY2026
- 219.18M USD
- Year-over-year change
- +4.6%
- 4-year CAGR
- +18.1%
| Period | Period end | Cash & Equivalents | YoY change |
|---|---|---|---|
| FY2026 | 2026-03-31 | 219.18M | +4.6% |
| FY2025 | 2025-03-31 | 209.61M | +116.6% |
| FY2024 | 2024-03-31 | 96.79M | -38.8% |
| FY2023 | 2023-03-31 | 158.03M | +40.1% |
| FY2022 | 2022-03-31 | 112.81M | — |
Cash & Equivalents vs competitors
How DOCS compares with its peers on the latest reported figures
- DOCS's Sep 2026 cash & equivalents of $218.61M is the 8th highest of the 10 companies compared; the peer median is $590.48M.
- Its year-over-year change of +29.2% is the 4th highest of 10, against a peer median of +3.1%.
- Cash & equivalents amounts to 20.0% of total assets for DOCS, versus a peer median of 5.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $1.03B | +77.0% | +38.7% | 54.5% | |
| Jul 2026 | $1.02B | +3.1% | +26.5% | 8.5% | |
| Jun 2026 | $928.38M | +137.8% | +30.9% | 5.7% | |
| Jun 2026 | $886.5M | +56.5% | +2.3% | 2.5% | |
| Sep 2026 | $590.48M | -10.0% | +25.9% | 24.1% | |
| Jun 2026 | $403M | -18.1% | +143.3% | 2.8% | |
| Jul 2026 | $256M | -15.9% | +7.8% | 7.8% | |
| Sep 2026 | $218.61M | +29.2% | +11.5% | 20.0% | |
| Jul 2026 | $154.7M | +23.9% | -7.2% | 1.2% | |
| Jun 2026 | $107.7M | -21.6% | +67.7% | 1.4% | |
| Peer median (excluding DOCS) | $590.48M | +3.1% | +26.5% | 5.7% | |
Competitors are the stored peer set for DOCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 | FY2026 Mar 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 112.81M | 158.03M | 96.79M | 209.61M | 219.18M |
| Short-term Investments | 685.3M | 682.97M | 666.12M | 706.05M | 529.42M |
| Net Receivables | 81.07M | 107.05M | 101.33M | 128.35M | 144.78M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 5.51M | 27.41M | 48.71M | 44.6M | 50.88M |
| Total Current Assets | 904.14M | 975.45M | 912.94M | 1.09B | 944.26M |
| Property, Plant & Equipment (Net) | 9.58M | 25.1M | 24.65M | 22.54M | 25.22M |
| Goodwill | 18.92M | 67.94M | 67.94M | 67.94M | 84.97M |
| Intangible Assets | 7.91M | 31.84M | 27.32M | 23.07M | 35.33M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 48.56M | 34.91M | 45.07M | 60.01M | 31.98M |
| Other Non-current Assets | 2.26M | 1.65M | 1.46M | 2.12M | 1.92M |
| Total Non-current Assets | 87.22M | 161.44M | 166.43M | 175.69M | 179.42M |
| Total Assets | 991.36M | 1.14B | 1.08B | 1.26B | 1.12B |
| Account Payables | 463K | 1.27M | 2.25M | 1.36M | 4.01M |
| Short-term Debt | 0 | 0 | 0 | 0 | 2.11M |
| Tax Payables | 785K | 1.5M | 14.02M | 1.36M | 0 |
| Deferred Revenue | 84.91M | 105.24M | 99.15M | 114.29M | 106.05M |
| Other Current Liabilities | 4.88M | 11.92M | 14.77M | 12.06M | 42.8M |
| Total Current Liabilities | 111.28M | 139.51M | 147.25M | 156.26M | 154.97M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 78K | 198K | 211K | 280K | 400K |
| Other Non-current Liabilities | 956K | 17.18M | 18.12M | 14.96M | 9.4M |
| Total Non-current Liabilities | 1.48M | 31.27M | 30.73M | 25.43M | 17.88M |
| Total Liabilities | 112.76M | 170.77M | 177.98M | 181.68M | 172.85M |
| Common Stock | 192K | 194K | 187K | 189K | 183K |
| Retained Earnings | 191.11M | 217.86M | 79.99M | 186.89M | (51.06M) |
| Accumulated OCI | (15.29M) | (14.08M) | (2.66M) | 1.32M | 28K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 878.59M | 966.12M | 901.4M | 1.08B | 950.84M |
| Total Debt | 1.09M | 15.64M | 14.55M | 12.4M | 10.19M |
| Net Debt | (111.72M) | (142.39M) | (82.24M) | (197.22M) | (208.99M) |
Doximity, Inc.
NYSE:DOCS
Intrinsic Alpha fair value
Locked
Current Price
$30.67
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.